Table 3 Follow-up data of HIV infected children in HIV clinics at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia from April 1 to May 15, 2018 (n = 318)
Variables | Â | N (%) |
|---|---|---|
Status Category | ||
 Alive on ART | 318 (92.4) | |
 Dead | 26 (7.6) | |
Duration of follow up(month) | ||
  ≤ 36 | 13 (4.1) | |
 37–59 | 31 (9.7) | |
  ≥ 60 | 274 (86.2) | |
Substitution of first line | ||
 Yes | 162 (50.9) | |
  Treatment failure | 72 (44.4) | |
  New drug available | 50 (30.8) | |
  Toxicity | 23 (14.1) | |
  Drug stock out | 6 (3.7) | |
  Change to fixed dose | 6 (3.7) | |
  New TB diagnosis | 2 (1.23) | |
  Others | 3 (1.85) | |
 No | 156 (49.05) | |
Time taken to initiate second line medication | ||
  < 4 weeks | 26 (36.1) | |
  ≥ 5 weeks | 46 (63.8) | |
Adherence status of past 6 month | ||
 Good | 269 (84.5) | |
 Fair | 37 (11.6) | |
 Poor | 12 (3.7) | |
WHO T stage | ||
 T1 | 289 (90.8) | |
 T2 | 7 (2.2) | |
 T3 | 1 (0.31) | |
 T4 | 21 (6.6) | |
Current CD4 count | ||
 Not-significant immunosuppression | 241(75.8) | |
 Mild-immunosuppression | 49 (15.4) | |
 Advanced-immunosuppression | 17 (5.3) | |
 Severe-immunosuppression | 11 (3.5) | |
Viral load test | ||
 Undetectable | 268 (84.2) | |
  ≥ 150 | 24 (7.5) | |
 Missing data | 26 (8.1) | |
Developed treatment failure to first line | ||
 Yes | 72 (22.6) | |
 Clinical failure only | 2 2.7 | |
 Immunological failure only | 37 (51.3) | |
 Virologic failure only | 6 (8.3) | |
 Clinical and immunological | 24 (33.3) | |
 Virologic and immunologic | 3 (4.17) | |
 No | 246 (77.4) | |